← Human Trials & Peer-Reviewed Studies
The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study
Plain-language guide to PMID 10857943 (2000): pilot randomized controlled trial study of Octreotide in 12 patients, diabetic retinopathy and glaucoma.
Key Facts
- PMID
- 10857943
- Journal
- Diabetes care
- Year
- 2000
- Study type
- Randomized Controlled Trial
- Authors
- Grant MB et al. (7 authors)
- DOI
- 10.2337/diacare.23.4.504
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide in the context of diabetic retinopathy and glaucoma in this randomized controlled trial publication.
The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease.
Who Took Part
The abstract describes 12 patients taking part.
PubMed tags the participants as both men and women.
Endocrine assessments occurred at 3-month intervals during the study.
How the Study Was Run
The design is described as randomized and pilot.
Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
It is described as a pilot, a small early test of whether a larger Octreotide study would be practical.
The methods mention a period of 15 months.
Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high-risk PDR requiring laser surgery.
What Was Measured
The subject headings attached to it are Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Disease Progression, Glycated Hemoglobin, Insulin-Like Growth Factor I and Octreotide.
What This Means in Plain Language
The paper is a randomized and pilot study of Octreotide in 12 patients in people with diabetic retinopathy and glaucoma over 15 months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2000 (Diabetes care), a journal based in United States.
More context: the Octreotide compound page, Diabetic retinopathy and glaucoma research.
Our Notes on the Compound
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.